-
公开(公告)号：US11883469B2
公开(公告)日：2024-01-30
申请号：US16956935
申请日：2018-12-19
IPC分类号： A61K38/39 , A61K47/58 , A61K47/64 , A61P25/00 , A61K9/00 , A61K9/70 , A61K47/18 , A61L27/18 , A61L27/22 , A61L27/24 , A61L27/56
CPC分类号： A61K38/39 , A61K9/0024 , A61K9/70 , A61K47/183 , A61K47/58 , A61K47/6435 , A61L27/18 , A61L27/227 , A61L27/24 , A61L27/56 , A61P25/00 , A61L2430/32
摘要： A polyacrylonitrile (PANi) based pharmaceutical composition providing a porous implant for use in treating spinal cord trauma and/or spinal cord injury. Particularly a pharmaceutical composition including polyacrylonitrile (PANi) and/or elastin (E) and/or collagen (C) to form a PANi-E and/or PANi-C and/or a PANi-EC polymer network. Particularly, a pharmaceutical composition including polyacrylonitrile (PANi), elastin (E), and collagen (C) together forming a polyacrylonitrile (PANi), elastin (E), collagen (C) polymer network (PANi-E-C), wherein the polyacrylonitrile (PANi) may be crosslinked to form a crosslinked interpenetrating polyacrylonitrile (PANi), elastin (E) and collagen (C) polymer network (xpi-PANi-E-C), and wherein secondary protein structures of elastin (E) and collagen (C) reorientate. The disclosure extends to use of the pharmaceutical composition in the treatment of spinal cord trauma and/or spinal cord injury.
-
2.发明公开公开(公告)号：US20230212250A1
公开(公告)日：2023-07-06
申请号：US17609731
申请日：2020-05-11
发明人： Stefan Franz Thomas WEISS , Katelyn CUTTLER , Tyrone Chad OTGAAR , Eloise VAN DER MERWE , Monique J. BIGNOUX
IPC分类号： C07K14/47 , C07K14/705 , C07K14/78
CPC分类号： C07K14/4711 , C07K14/705 , C07K14/78
摘要： This disclosure relates to a method of decreasing concentration of tau (τ) protein and/or phosphorylated tau (τ) protein in a target cell of a human or animal subject having Alzheimer's Disease (AD). The disclosure extends to use of biopharmaceutical agents including (i). 37 kDa/67 kDa laminin receptor precursor/high affinity laminin receptor (LRP/LR) and/or a fragment thereof, or (ii). a transfecting agent for the expression of LRP/LR, for use in treating Alzheimer's Disease (AD).
-
公开(公告)号：US20230112176A1
公开(公告)日：2023-04-13
申请号：US17910022
申请日：2021-03-11
发明人： Nosipho MOLOTO , Kalenga MUBIAYI , Grace NGUBENI
摘要： This disclosure relates to the manufacture an alkali metal quaternary crystalline nanomaterial. an alkali metal quaternary crystalline nanomaterial having general Formula A (I2-II-IV-VI4); and wherein I is sodium (Na) or lithium (Li), II and IV are Zn or Sn, and VI is a chalcogens selected from the group comprising: sulphur (S), selenium (Se) or tellurium (Te). The crystal phase of the alkali metal quaternary crystalline nanomaterial may be a primitive mixed Cu—Au like structure (PMCA) and may have a space group: P42m. The nanomaterials may be adapted to provide a solar cell. Methods of manufacture are also provided.
-
公开(公告)号：US20210277084A1
公开(公告)日：2021-09-09
申请号：US17258217
申请日：2019-07-08
发明人： Stefan Franz Thomas WEISS , Tyrone Chad OTGAAR , Eloise VAN DER MERWE , Martin BERNERT , Gavin MORRIS
IPC分类号： C07K14/705 , A61P3/04 , A61P5/50
摘要： A biopharmaceutical agent including a 37 kDa/67 kDa laminin receptor precursor/high affinity laminin receptor (LRP/LR) and/or a fragment thereof for use in treatment and/or prevention of atherosclerosis and/or obesity and/or insulin resistance and/or diabetes. The biopharmaceutical agent may be encapsulated by functionalized or non-functionalized nanoparticles, and further may be formulated to include a carrier to provide a pharmaceutical composition for parental or non-parental administration. In use, the biopharmaceutical agent reduces lipid content in target cells. Also, a method of decreasing lipid concentration in a target cell of a human or animal subject.
-
公开(公告)号：US10675592B2
公开(公告)日：2020-06-09
申请号：US15735628
申请日：2016-05-30
IPC分类号： B01D61/02 , B01D69/02 , B01D69/06 , B01D69/14 , B01D71/02 , B01D71/68 , C02F1/44 , C02F101/20 , C02F103/10 , B01D67/00
摘要： An acid mine drainage (AMD) treatment means comprising polyethersulfone (PES) having dispersed therein hydroxy-sodalite (H-SOD) so as to form a membrane is described. The PES-H-SOD membrane is suitable for treatment of acid mine drainage (AMD) by providing a filtration means to remove toxic chemicals, including but not limited to heavy metals. The invention extends to a method of manufacturing the acid mine drainage (AMD) treatment means.
-
公开(公告)号：US20150209275A1
公开(公告)日：2015-07-30
申请号：US14427195
申请日：2013-09-11
发明人： Yahya Essop Choonara , Lisa Claire du Toit , Pradeep Kumar , Viness Pillay , Raeesa M. Moosa , Rafeeq Jhetam
IPC分类号： A61K9/00 , A61K31/5377 , A61K31/196 , A61K9/20
CPC分类号： C07H15/02 , A61K9/0051 , A61K9/2013 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2059 , A61K9/2072 , A61K9/2077 , A61K9/2095 , A61K31/138 , A61K31/196 , A61K31/4196 , A61K31/5377 , A61K45/06
摘要： This invention relates to a pharmaceutical dosage form, particularly to a topical ocular pharmaceutical dosage form comprising a polymeric matrix of polyethylene oxide block copolymer, preferably polyoxyethylene-polyoxypropylene block copolymer and hydroxpropyl cellulose, and a pharmaceutically active ingredient incorporated within the matrix. The invention extends to a method of manufacturing the pharmaceutical dosage form.
摘要翻译： 本发明涉及一种药物剂型，特别涉及包含聚环氧乙烷嵌段共聚物，优选聚氧乙烯 - 聚氧丙烯嵌段共聚物和羟丙基纤维素的聚合物基质的局部眼用药物剂型，以及并入基质内的药物活性成分。 本发明延伸到制造药物剂型的方法。
-
公开(公告)号：US20150076056A1
公开(公告)日：2015-03-19
申请号：US14490396
申请日：2014-09-18
CPC分类号： B01D71/68 , B01D67/0009 , B01D67/0011 , B01D67/0013 , B01D67/0079 , B01D67/0083 , B01D67/0088 , B01D67/0093 , B01D69/12 , B01D69/148 , B01D71/021 , B01D71/38 , B01D2323/02 , B01D2323/30
摘要： The present disclosure relates to a device for use in fluid purification, particularly to a membrane for use in fluid purification, the membrane comprising a porous basal layer in the form of polysulfone (PSF); a multitude of multi-walled carbon nanotubes (CNTs) dispersed within the basal layer; and a top layer in the form of polyvinyl alcohol (PVA). The disclosure extends to a method of manufacturing the device.
摘要翻译： 本公开涉及用于流体净化的装置，特别是用于流体净化的膜，所述膜包括聚砜形式的多孔基底层（PSF）; 分散在基底层内的多个多壁碳纳米管（CNT）; 和聚乙烯醇（PVA）形式的顶层。 本公开延伸到制造该装置的方法。
-
公开(公告)号：US20140148495A1
公开(公告)日：2014-05-29
申请号：US14057786
申请日：2013-10-18
IPC分类号： A61K9/00
CPC分类号： A61K9/2009 , A61K9/0024 , A61K9/204
摘要： An improved monolithic drug delivery dosage form releases a pharmaceutically active agent at a predetermined rate. The dosage form comprises a salted-out or crosslinked polymer and a pharmaceutically active agent. The salted-out or crosslinked polymer functions to polymerically entangle the pharmaceutically active agent but, progressively relaxes on contact with an aqueous medium in use to release the pharmaceutically active agent at a predetermined rate.
摘要翻译： 改进的整体药物递送剂型以预定的速率释放药物活性剂。 该剂型包含盐析或交联的聚合物和药物活性剂。 盐析或交联的聚合物用于使药物活性剂聚合缠结，但是在使用中与水性介质接触时逐渐松弛，以预定的速率释放药物活性剂。
-
公开(公告)号：US11329809B2
公开(公告)日：2022-05-10
申请号：US16480008
申请日：2018-01-23
摘要： This invention relates generally to a method and system for hybrid classical-quantum communication. The method comprises transmitting a single photon having a particular quantum state over a communication medium using a quantum mode set; and transmitting a classical light beam over the same communication medium using a classical mode set, wherein the classical and quantum mode sets comprise non-separable modes in common. The non-separable modes in common may be two degrees of freedom of a single photon or classical light and may thus be spatial modes in one or more indexes, and polarisation. The invention relates also to a system to implement the method accordingly.
-
公开(公告)号：US20220096529A1
公开(公告)日：2022-03-31
申请号：US17426780
申请日：2020-01-28
发明人： Mandeep KAUR , Sourav Taru SAHA
IPC分类号： A61K31/724 , A61P35/00
摘要： A method including the step of administering 2-hydroxypropyl-β-cyclodextrin (HPβCD) for use in the treatment of breast cancer. Particularly, this invention relates to HPβCD for use in the treatment of triple negative breast cancer, wherein the HPβCD is for administration to a patient in need thereof. The invention extends to methods of preparing a pharmaceutical composition comprising HPβCD, and further extends to a method of treating breast cancer, typically triple negative breast cancer, by administration of the composition to a patient in need thereof.
-
-
-
-
-
-
-
-
-
搜索结果
65 条记录 (耗时 0.029 秒)
